BioMarin's (BMRN) NDA Acceptance for Drisapersen an 'Incremental Positive', Baird Says

Baird analyst Brian Skorney reiterated a Neutral rating and $133 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), saying the Drisapersen NDA acceptance an incremental positive.

Skorney commented, "The FDA's acceptance of the drisapersen NDA comes, as expected, with priority review and a late-December PDUFA. We continue to have little visibility into the FDA decision as we believe success will be contingent not only on drisapersen's acceptance but eteplirsen's rejection and see compelling reasons for the agency to go in any direction."

For an analyst ratings summary and ratings history on BioMarin Pharmaceutical Inc. click here. For more ratings news on BioMarin Pharmaceutical Inc. click here.

Shares of BioMarin Pharmaceutical Inc. closed at $134.84 yesterday.

You May Also Be Interested In

• HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
• Synovus Financial (SNV) PT Lowered to $42 at Piper Sandler
• Truist Securities Assumes BioMarin Pharmaceutical Inc. (BMRN) at Buy